Atriyal fibrilasyon hastalarında gerçek yaşam antikoagülan tedavi tercihlerinin değerlendirilmesi: Çok merkezli ROTA Çalışması verileri

Basit Öğe Kaydı
dc.authorscopusid57211015002
dc.authorscopusid25951372300
dc.authorscopusid55457354700
dc.authorscopusid57217249933
dc.authorscopusid57202391627
dc.authorscopusid57197876302
dc.authorscopusid23979295100
dc.contributor.authorKocabaş, U.
dc.contributor.authorErgin, I.
dc.contributor.authorYavuz, V.
dc.contributor.authorMurat, S.
dc.contributor.authorÖzdemir, I.
dc.contributor.authorGenç, Ö.
dc.contributor.authorAltın, C.
dc.date.accessioned2024-08-25T18:45:33Z
dc.date.available2024-08-25T18:45:33Z
dc.date.issued2023
dc.departmentEge Üniversitesien_US
dc.description.abstractOBJECTIVE: Oral anticoagulant therapy is the cornerstone of atrial ?brillation management to prevent stroke and systemic embolism. However, there is limited real-world information regarding stroke and systemic embolism prevention strategies in patients with atrial ?brillation. The aim of the ROTA study is to obtain the real-world data of anticoagulant treatment patterns in patients with atrial ?brillation. METHODS: The ROTA study is a prospective, multicenter, and observational study that included 2597 patients with atrial ?brillation. The study population was recruited from 41 cardiology outpatient clinics between January 2021 and May 2021. RESULTS: The median age of the study population was 72 years (range: 22-98 years) and 57.4% were female. The median CHA2DS2-VASc and HAS-BLED scores were 4 (range: 0-9) and 1 (range: 0-6), respectively. Vitamin K antagonists and direct oral anticoagulants were used in 15.9% and 79.4% of patients, respectively. The mean time in therapeutic range was 52.9% for patients receiving vitamin K antagonists, and 76% of those patients had an inadequate time in therapeutic range with <70%. The most common prescribed direct oral anticoagulants were rivaroxaban (38.1%), apixaban (25.5%), and edoxaban (11.2%). The rate of overuse of vitamin K antagonists and direct oral anticoagulants was high (76.1%) in patients with low stroke risk, and more than one-fourth of patients on direct oral anticoagulant therapy were receiving a reduced dose of direct oral anticoagulants. Among patients who were on direct oral anticoagulant treatment, patients with apixaban treatment were older, had higher CHA2DS2-VASc and HAS-BLED scores, and had lower creatinine clearance than the patients receiving other direct oral anticoagulants. CONCLUSIONS: The ROTA study provides important real-world information about anticoagulant treatment patterns in patients with atrial ?brillation.time in therapeutic range with <70%.en_US
dc.identifier.doi10.5543/tkda.2022.98455
dc.identifier.endpage96en_US
dc.identifier.issn1308-4488
dc.identifier.issue2en_US
dc.identifier.pmid36916815en_US
dc.identifier.scopus2-s2.0-85150311273en_US
dc.identifier.scopusqualityQ4en_US
dc.identifier.startpage88en_US
dc.identifier.urihttps://doi.org/10.5543/tkda.2022.98455
dc.identifier.urihttps://hdl.handle.net/11454/101609
dc.identifier.volume51en_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherNLM (Medline)en_US
dc.relation.ispartofTurk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidiren_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.snmz20240825_Gen_US
dc.subjectanticoagulant agenten_US
dc.subjectdabigatranen_US
dc.subjectdipyroneen_US
dc.subjectrivaroxabanen_US
dc.subjectvitamin K groupen_US
dc.subjectadulten_US
dc.subjectageden_US
dc.subjectatrial fibrillationen_US
dc.subjectcerebrovascular accidenten_US
dc.subjectclinical trialen_US
dc.subjectcomplicationen_US
dc.subjectembolismen_US
dc.subjectfemaleen_US
dc.subjecthumanen_US
dc.subjectmaleen_US
dc.subjectmiddle ageden_US
dc.subjectmulticenter studyen_US
dc.subjectoral drug administrationen_US
dc.subjectprospective studyen_US
dc.subjectvery elderlyen_US
dc.subjectyoung adulten_US
dc.subjectAdministration, Oralen_US
dc.subjectAdulten_US
dc.subjectAgeden_US
dc.subjectAged, 80 and overen_US
dc.subjectAnticoagulantsen_US
dc.subjectAtrial Fibrillationen_US
dc.subjectDabigatranen_US
dc.subjectEmbolismen_US
dc.subjectFemaleen_US
dc.subjectHumansen_US
dc.subjectMaleen_US
dc.subjectMiddle Ageden_US
dc.subjectProspective Studiesen_US
dc.subjectPyridonesen_US
dc.subjectRivaroxabanen_US
dc.subjectStrokeen_US
dc.subjectVitamin Ken_US
dc.subjectYoung Adulten_US
dc.titleAtriyal fibrilasyon hastalarında gerçek yaşam antikoagülan tedavi tercihlerinin değerlendirilmesi: Çok merkezli ROTA Çalışması verilerien_US
dc.title.alternativeReal-World Evaluation of Anticoagulant Treatment Patterns in Patients with Atrial Fibrillation: Data from Multicenter ROTA Studyen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu